

Vaccine against CMV Associated Brain Cancer is in Development; The CBCD Reviews a Report

VBI Vaccines Inc. (Nasdaq:VBIV) is developing a vaccine against glioblastoma multiforme ("Glioblastoma" or "GBM"), which is associated with CMV infection. (1)

ROCHESTER, NY, UNITED STATES,
October 18, 2015 /EINPresswire.com/ --

"Infected with the cytomegalovirus (CMV)? The CBCD recommend taking [Gene-Eden-VIR](#) or [Novirin](#)." – Greg Bennett, CBCD

The biopharmaceutical company VBI Vaccines, Inc. ("VBI") announced on October 8, 2015 that it would begin development of a new therapeutic vaccine designed to fight CMV associated brain cancer (glioblastoma multiforme). In fact, "Columbia University's Brain Tumor Center is performing research to evaluate VBI's GBM immunotherapy candidate in ex vivo studies using GBM patient samples." (1) Importantly, "glioblastoma is among the most common and aggressive malignant primary brain tumors in humans. In the U.S. alone, 12,000 new cases are diagnosed each year. The current standard of care for GBM is surgical resection, followed by radiation and chemotherapy. Even with aggressive treatment, GBM progresses rapidly and is exceptionally lethal, with median patient survival of less than sixteen months. A growing body of research has demonstrated that GBM tumors are particularly susceptible to infection by cytomegalovirus ("CMV"), with over 90%

of GBM tumors expressing CMV antigens." (1)

Developing an effective, therapeutic vaccine against CMV infected brain tumors and gaining FDA approval takes time. Until VBI's new vaccine undergoes human clinical trials, and the vaccine gains FDA approved, the CBCD recommends that infected



Click to learn more about [CMV symptoms](#).

The formula of Gene-Eden-VIR and Novirin was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Gene-Eden-VIR and Novirin formula is effective against the herpes family of viruses, including the human cytomegalovirus (CMV). The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the CMV ... reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (2) The study authors also wrote that, “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (2)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites, here:

<http://www.gene-eden-vir.com>

and

<http://www.novirin.com>

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

Concerning VBI's new vaccine candidate, Dr. David E. Anderson said that “Recent advances in this field are promising, but there is still need for improved CMV vaccination approaches for GBM, our eVLP approach has allowed for the efficient delivery of multiple CMV antigens, and in the case of GBM, we believe could be capable of mobilizing a broad and robust anti-tumor immune response against GBM.” (1) Dr. Anderson is VBI's Chief Scientific Officer.

What treatments are available against the cytomegalovirus?

“Several drugs are approved for the treatment of CMV infections in immunocompromised individuals. These drugs include ganciclovir, its oral prodrug valganciclovir, cidofovir, foscavir and fomivirsen. However, the use of these drugs in immunocompetent individuals is limited by their toxicity, poor oral bioavailability, modest efficacy, and the development of drug resistance.” (3) There are also two natural CMV remedies with a clinically proven formula.

In light of the fact that there are no vaccines against the CMV currently on the market, the CBCD recommends that CMV infected individuals take Novirin or Gene-Eden-VIR against the latent virus.

Find us on Facebook here: <https://www.facebook.com/GeneEdenVIR>

Follow us Twitter here: @HananPolansky

All orders of Gene-Eden-VIR and Novirin are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) VBI Vaccines - "VBI Vaccines Announces Development of a Novel Glioblastoma Immunotherapy Candidate" - Nasdaq GlobeNewswire

(2) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.

<http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101>

Greg Bennett
CBCD
585-250-9999
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.

